Phase I, Randomized, Double-blinded, Placebo-Controlled Dose De-escalation Study to Evaluate the Safety and Immunogenicity of Alum Adjuvanted Zika Virus Purified Inactivated Vaccine (ZPIV) Administered by the Intramuscular Route in Adult Subjects Who Reside in a Flavivirus Endemic Area
Phase of Trial: Phase I
Latest Information Update: 30 Mar 2017
At a glance
- Drugs Zika virus vaccine-Sanofi (Primary)
- Indications Zika virus infection
- Focus Adverse reactions
- 16 Mar 2017 Status changed from not yet recruiting to recruiting.
- 26 Jan 2017 Planned End Date changed from 1 Jan 2020 to 15 Jan 2020.
- 26 Jan 2017 Planned primary completion date changed from 1 Jul 2019 to 18 Jul 2019.